Lipids and lipid nanoparticle formulations for delivery of nucleic acids

Inventors

Ansell, Steven M. • Du, Xinyao

Assignees

Acuitas Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10723692-B2

Patent

Publication Date

2020-07-28

Expiration Date


Abstract

Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Core Innovation

The invention relates to a compound having structure (II), including R10 and R11 each independently being a straight, saturated alkyl chain containing from 12 to 16 carbon atoms. The parameter z is selected such that the polyethyleneglycol (PEG) portion of structure (II) has an average molecular weight of about 2000 to 6000 g/mol, defining a specific chemical scope for the pegylated lipid structure.

The compounds are described as components for lipid nanoparticles, together with a cationic lipid as defined in Formula (I), optional neutral lipids, and cholesterol or a steroid. In these embodiments, therapeutic nucleic acids are included, including antisense oligonucleotide, plasmid DNA, messenger RNA, siRNA, miRNA inhibitors, antagomirs, and antimirs.

The document also describes luciferase-based liver transfection assay results comparing novel cationic lipid formulations, with pKa values provided for the lipid variants. The data are presented to evidence differences in luciferase performance associated with the novel cationic lipid structures and to link PEG portion selection, alkyl chain structure, and measured luciferase performance.

Claims Coverage

The provided claim set includes one independent claim. The inventive content is centered on a specific compound structure (II) with constrained alkyl chain lengths and a PEG-molecular-weight selection via z, and then extends to lipid nanoparticles comprising that compound.

Pegylated ionizable cationic lipid structure with constrained alkyl chain lengths and PEG molecular weight

A compound having structure (II), wherein R10 and R11 are each independently a straight, saturated alkyl chain containing from 12 to 16 carbon atoms, and z is selected such that the polyethyleneglycol (PEG) portion of structure (II) has an average molecular weight of about 2000 to 6000 g/mol.

Lipid nanoparticle comprising the defined compound

A lipid nanoparticle that comprises the compound recited in claim 1.

Overall, the claim coverage focuses on a pegylated ionizable cationic lipid compound defined by constrained R10/R11 chain length and PEG average molecular weight selection, and on lipid nanoparticle formulations that include that compound.

Stated Advantages

Serum protection via nuclease resistance/serum stability.

Improved intracellular delivery via endosomolytic ionization.

Suitable systemic delivery.

Improved tolerability.

Increased therapeutic index.

Provides luciferase-based liver transfection activity data showing wide variation across different novel cationic lipid structures.

Documented Applications

Therapeutic delivery of human FIX (hFIX) mRNA, with ELISA-measured hFIX protein levels in mouse plasma.

Delivery of therapeutic nucleic acids in vitro and in vivo, including mRNA, antisense oligonucleotides, siRNA/miRNA inhibitors (antagomirs/antimirs), and plasmid DNA.

In vivo delivery and assessment of mRNA expression in mouse liver after tail-vein injection using luciferase expression measurements, including evaluation across multiple mRNA doses and comparative assessment related to amino lipid hydrocarbon chain structure and headgroup chain length.

In vivo expression kinetics assessment using cherry red (CR) mRNA formulated with lipid nanoparticles, including measurement of expression duration.

PEG-lipid comparative evaluation using PEG-DMG versus PEG-DMA in the context of the disclosed in vivo expression measurements.

pKa characterization of disclosed cationic lipid/LNP compounds using a TNS fluorescence assay across pH with fluorescence intensity measurements and sigmoidal best fit analysis.

Use of lipid nanoparticles for systemic delivery.

Luciferase-based liver transfection assay using novel cationic lipid formulations, with luciferase expression measured after tail vein injection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.